Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Peking University People's Hospital300 enrolled

Overview

Colorectal carcinoma with liver metastasis is one of the major problems bothering physicians worldwide. Bevacizumab combined with chemotherapy is the standard treatment recommended by several guidelines. Despite the high cost, a certain portion of patients couldn't benefit from this therapy. This study is aiming to find out the specific type of patients who would respond to bevacizumab by Radiomics approach, and evaluate the prediction value of this imaging model with clinical and genetic factors.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Colon Cancer Rectal Cancer Liver Metastases

Interventions

BevacizumabDRUG

bevacizumab combined with chemotherapy

Medical Language ↔ Plain English

Inclusion Criteria: 1. Colorectal carcinoma confirmed by pathological result. 2. Liver metastasis confirmed by imaging studies. 3. Treatment of bevacizumab combined with chemotherapy chosen by MDT team. 4. ECOG: 0-2. 5. Normal laboratory studies including liver\\renal\\bone marrow functions. 6. Expected lifespan more than 3 months. Exclusion Criteria: 1. Previous treatment of colorectal cancer with liver metastasis. 2. Diagnosed with other malignancies. 3. Couldn't finish the trial due to several reasons such as allergy to chemotherapy drugs\\pregnancy or lactation\\chronic heart disease\\unable to sustain further treatment.

Outcomes

Primary Outcomes

estimated ORR

Time frame: 6-8 weeks

Secondary Outcomes

estimated PFS

Time frame: 3 years

estimated OS